TD Cowen Reiterates Buy Rating on ICON Public Limited Company
TD Cowen maintains a buy rating on ICON PLC with a $197 target price, a 15.98% upside from the current price.
Key Points
- TD Cowen reiterated its buy rating on ICON Public Limited Company (NasdaqGS: ICLR) with a target price of $197.
- TD Cowen's $197 price target implies 15.98% upside from ICON Public Limited Company's ($ICLR) current $169.86 share price.
- Shares of ICON PLC traded at $158.17 on Thursday, with a market cap of $10.78 billion and a P/E ratio of 48.36.
- RBC Capital upgraded ICON to buy with a $185 target, while analysts maintain a consensus buy rating with a $154.19 mean target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
TD Cowen has reiterated its buy rating on ICON Public Limited Company (NasdaqGS: ICLR) with a target price of $197. This decision was announced on June 25, 2026, by analyst Charles Rhyee. On the same day, shares of ICON traded at $158.17.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ICON Public Limited Company Stock Down 0.1%
Shares of ICON Public Limited Company, trading under the ticker ICLR on the NasdaqGS, were seen around $158.17 on Thursday. The company has a market capitalization of approximately $10.78 billion. ICON's P/E ratio stands at 48.36, while its forward P/E is 12.03, indicating expectations of future earnings growth. The stock has been volatile, with a 52-week range between $66.57 and $211.00. It has a 50-day moving average of $124.49 and a 200-day moving average of $149.71.
$ICLR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, RBC Capital upgraded ICON to a buy rating with a $185 target. TD Cowen maintained its buy rating with a $197 target. JP Morgan held a neutral stance with a hold rating and a $155 target, while Evercore ISI Group and Baird also reiterated buy ratings with targets of $180 and $186, respectively. B of A Securities maintained a sell rating with a $150 target. Overall, the consensus among 16 analysts is a buy rating with a mean price target of $154.19.
Other Institutional Activity in ICON
Several institutional investors have adjusted their stakes in ICON. Artisan Partners Limited Partnership increased its holdings by 1,404,968 shares, bringing its total to 8,278,945 shares valued at approximately $916.1 million. Wellington Management Group LLP added 1,562,287 shares, ending with 5,913,037 shares worth about $654.3 million. Harris Associates L P significantly increased its position by 1,841,151 shares, now holding 4,351,317 shares valued at $481.5 million. FMR LLC boosted its stake by 1,076,111 shares to 4,174,006 shares, valued at $461.9 million. Invesco Ltd. marginally increased its holdings by 121,973 shares, reaching 3,878,869 shares valued at $429.2 million.
Insider Buying and Selling at ICON Public Limited Company
On May 14, 2026, several insiders made transactions involving ICON shares. Dr. John Climax bought and sold 5,005 shares on the same day. Ronan Martin Murphy also bought and sold 5,005 shares each. Eugene Pacelli McCague purchased and sold 3,255 shares on the same date. These transactions were not part of a pre-planned trading scheme.
About ICON Public Limited Company
ICON Public Limited Company, headquartered in Dublin, Ireland, is a global clinical research organization. It offers outsourced development and commercialization services across various regions including Ireland, Europe, and the United States. The company specializes in clinical trial management, commercial services, and laboratory services. ICON serves the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. With a workforce of about 40,100 employees, ICON is led by CEO Mr. Barry Balfe.
Bottom Line
TD Cowen's reiteration of a buy rating on ICON Public Limited Company highlights continued confidence in the company's future performance. Investors and analysts closely watch these ratings as they provide insights into market expectations. Remember, 13F filings and analyst ratings are backward-looking and may not reflect the most current market conditions.
Get ICON Public Limited Company alerts
New 13F filings, insider trades, and analyst moves on $ICLR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.